Sarepta Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Sarepta is a development-stage biopharmaceutical company focused on RNA-based therapeutics for rare and infectious diseases. Its principal programs were eteplirsen and other exon-skipping candidates for Duchenne muscular dystrophy (DMD), and AVI-7288 for Marburg virus. The filing covers the three months ended March 31, 2014, with unaudited U.S. GAAP financial statements.
Financial Performance and Position
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue from license fees, grants and research contracts | $6.1 million | $4.5 million | +36% |
| Research and development expense | $20.9 million | $13.8 million | +52% |
| General and administrative expense | $10.3 million | $6.1 million | +68% |
| Operating loss | $25.1 million | $15.4 million | Higher loss |
| Net loss | $28.3 million | $42.1 million | Loss decreased 33% |
| Basic and diluted loss per share | $0.75 | $1.32 | Improved |
| Net cash used in operating activities | $28.3 million | $15.0 million | Higher use |
Revenue was generated primarily from government research contracts and grants, not product sales. Q1 revenue included $4.1 million from the Marburg contract, $1.4 million from the SKIP-NMD DMD agreement and $0.7 million from the Children’s National Medical Center agreement. The SKIP-NMD and CNMC arrangements were fully recognized by March 31, 2014.
At March 31, 2014, Sarepta reported total assets of $275.4 million, including $49.1 million of cash and cash equivalents, $176.1 million of short-term investments and $7.9 million of restricted investments. Cash, cash equivalents and short-term investments totaled $225.2 million; including restricted investments, cash, cash equivalents and investments totaled $233.1 million.
Total liabilities were $46.4 million, including $1.6 million of long-term debt, $9.2 million of warrant liability and $3.3 million of deferred revenue. The accumulated deficit was $571.5 million. Margins were not economically meaningful because the company remained substantially loss-making and had no material product sales.
Material Changes Versus the Prior Comparable Period
- Revenue increased 36%, primarily from higher Marburg and DMD-related contract activity, partly offset by completion of the August 2012 intramuscular contract.
- Research and development expense increased $7.1 million, driven by higher headcount, external DMD program spending, eteplirsen NDA preparation, facility costs and a patent assignment payment. Infectious disease spending declined as the intramuscular contract was completed.
- General and administrative expense increased $4.2 million due primarily to higher headcount-related costs, consulting fees and legal fees.
- The warrant valuation loss declined to $3.3 million from $26.9 million, substantially reducing the net loss. The warrant liability is non-cash and is remeasured using a Black-Scholes-Merton model.
- Cash and cash equivalents declined by $207.9 million during the quarter, primarily because Sarepta invested $176.7 million in short-term securities and used $28.3 million in operating activities. Property and equipment purchases totaled $5.3 million.
- Stock-based compensation increased to $4.3 million from $1.7 million.
- Common shares outstanding increased to approximately 38.0 million at March 31, 2014 from 37.8 million at December 31, 2013.
Guidance, Outlook, Risks and Unusual Items
- On April 21, 2014, management announced plans to submit an NDA for eteplirsen by the end of 2014 and to begin additional eteplirsen and follow-on exon-skipping studies, subject to FDA feedback and execution.
- On April 29, 2014, Sarepta sold 2.65 million common shares at $38.00 per share and received approximately $94.5 million in net proceeds. Management stated that, including these proceeds and considering outstanding warrants, available resources were sufficient to fund the current operational plan for the next twelve months.
- The Marburg contract includes potential funding of approximately $84.4 million for later segments, but the Department of Defense has discretion whether to exercise those options. Government funding is subject to appropriations, audits, delays and termination for convenience.
- Sarepta had $165.4 million of non-cancelable purchase commitments and $27.4 million of operating lease commitments as of March 31, 2014. Restricted investments included $7.3 million supporting letters of credit for manufacturing commitments.
- The company has not generated material product-sale revenue and expects to continue incurring operating losses. Future financing may be required, creating potential dilution or unfavorable financing terms.
- Pending legal matters included a former consultant’s claim seeking approximately $4 million and securities class actions concerning disclosures about eteplirsen. The filing states that the outcomes and potential material impact could not yet be assessed.
- FDA approval of eteplirsen is uncertain. The FDA questioned the use of dystrophin as a biomarker and the efficacy support provided by the six-minute walk test, and may require additional data, studies or manufacturing work.
- Additional risks include clinical-trial failure or delay, dependence on third-party manufacturers, intellectual-property claims, reliance on government contracts, competition and stock-price volatility. Management stated that controls implemented during Q1 addressed a material weakness identified at December 31, 2013 relating to review of significant research and development contracts.
Important Facts for Investors to Verify
- Whether the eteplirsen NDA was submitted by the targeted year-end 2014 timeframe and whether the FDA accepted, reviewed or approved it.
- Whether the Department of Defense exercised later Marburg contract segments and whether government funding or audits affected revenue recognition.
- The pace of cash burn, investment liquidity and the duration of funding after the April 2014 equity offering.
- Clinical-trial results, confirmatory-study requirements, manufacturing scale-up and FDA conclusions regarding eteplirsen efficacy and safety.
- The status and potential exposure from the consultant claim and securities class actions.
- Potential dilution from the 5.4 million shares subject to outstanding equity awards, approximately 0.6 million shares underlying warrants, and future equity financing.